From the ∗Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine
†Department of Hematology and Medical Oncology, Emory University School of Medicine, and the Winship Cancer Institute of Emory University, Atlanta, GA.
Received for publication September 26, 2022; revision accepted November 15, 2022.
Conflicts of interest and sources of funding: D.M.S. is consultant to Syncona, AIM Specialty Health, Global Medical Solutions Taiwan, Progenics Pharmaceuticals Inc, and Heidelberg University. He participates through the Emory Office of Sponsored Projects in full compliance with Emory University–sponsored research and conflict of interest regulations in sponsored grants including those funded or partially funded by Blue Earth Diagnostics, Ltd; Nihon MediPhysics Co, Ltd.; Telix Pharmaceuticals (US) Inc; Advanced Accelerator Applications; FUJIFILM Pharmaceuticals USA, Inc; and Amgen Inc; educational: School of Breast Oncology; PrecisCa. The other authors have no conflicts to report.
Author Contributions: C.W.: data collection, article drafting. C.M.: critical revision of the article, final approval of the version to be published. Y.B.: critical revision of the article. O.K.: patient collection, critical revision of the article. D.M.S.: critical revision of the article.
Correspondence to: Charles Marcus, MD, 1364 Clifton Rd NE, 1st FL #E163, Atlanta, GA 30322. E-mail: [email protected].